Diabetes

BOSTON — People with lower percentages of body fat are not necessarily at lower risk for diabetes and heart disease, according to a new international study.

The study identified a gene that is linked with having less body fat but also with having an increased risk of Type 2 diabetes and heart disease. The investigators examined the genomes of more than 75,000 people and found that the gene, IRS1, was linked to less body fat, but also to unhealthy levels of cholesterol and blood glucose.

SAN DIEGO — Patients with Type 1 diabetes using an insulin product made by MannKind expressed a better opinion about insulin therapy than those taking the standard treatment, according to a study presented at the American Diabetes Association’s 71st Scientific Sessions.

MannKind said that patients taking the investigational inhaled insulin Afrezza (insulin human [rDNA origin]) with basal insulin came to view insulin therapy more positively during the 16-week study than those taking Eli Lilly’s injected Humalog (insulin lispro [rDNA origin]) with basal insulin.

FRESNO, Calif. — Consuming nuts in place of carbohydrates may help improve long-term blood-sugar control and lower cholesterol levels among Type 2 diabetics, according to a new study.

SAN DIEGO — Adding an investigational drug for Type 2 diabetes to the common generic drug metformin helped control blood sugar in patients who could not control their blood sugar with metformin alone, according to results of a late-stage clinical study.

SAN DIEGO — A cobranded Type 2 diabetes treatment may help reduce blood-sugar levels among patients when combined with insulin (with or without metformin), according to a late-stage clinical trial.

AstraZeneca and Bristol-Myers Squibb said that when Onglyza (saxagliptin) in the 5-mg strength was combined with insulin (with or without metformin), patients saw significantly lower HbA1C levels by an average of about 0.73% by the end of the phase-3 trial, compared with a placebo-insulin (with or without metformin) combination.

SAN DIEGO — New data from a late-stage clinical trial of a recently approved drug for Type 2 diabetes show improved blood-sugar control in adults who take it with metformin or alone.

Boehringer Ingelheim and Eli Lilly presented data from the study of Tradjenta (linagliptin) at the American Diabetes Association’s 71st Scientific Sessions in San Diego last weekend. The study showed reductions in blood sugar and weight, and a low incidence of abnormally low blood sugar, known as hypoglycemia.

The FDA approved Tradjenta as a treatment for Type 2 diabetes in May.

PARIS — An investigational Sanofi drug for diabetes works at least as well as a similar treatment already on the market, and results in less abnormally low blood sugar, according to late-stage clinical trial results presented at the American Diabetes Association’s 71st Scientific Sessions in San Diego this past weekend.

PARIS — A new study indicated that two insulin products made by French drug maker Sanofi lower blood-glucose levels to a greater extent than premixed insulin, and with improvements in quality of life and less hypoglycemia.

Sanofi announced results of the 60-week study, which compared regimens, including Lantus (insulin glargine [rDNA origin]) and Apidra (insulin glulisine [rDNA origin]).